Literature DB >> 18357769

Preferential coxsackievirus replication in proliferating/activated cells: implications for virus tropism, persistence, and pathogenesis.

R Feuer1, J L Whitton.   

Abstract

Coxsackieviruses cause substantial human morbidity and mortality, but the underlying molecular mechanisms of disease remain obscure. Here, we review the effects that the cell status--both cellular activation, and the cell cycle--may have on the outcome of virus infection. We propose that these viruses have evolved to undergo productive infection in cells at the G1/S stage of the cell cycle, and to preferentially establish persistence/latent infection in quiescent cells, and we provide possible explanations for these outcomes. Finally, we consider the implications of these interactions for virus transmission and host pathology.

Entities:  

Mesh:

Year:  2008        PMID: 18357769     DOI: 10.1007/978-3-540-75546-3_7

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  16 in total

1.  Neural stem cell depletion and CNS developmental defects after enteroviral infection.

Authors:  Chelsea M Ruller; Jenna M Tabor-Godwin; Donn A Van Deren; Scott M Robinson; Sonia Maciejewski; Shea Gluhm; Paul E Gilbert; Naili An; Natalie A Gude; Mark A Sussman; J Lindsay Whitton; Ralph Feuer
Journal:  Am J Pathol       Date:  2011-12-31       Impact factor: 4.307

2.  A novel population of myeloid cells responding to coxsackievirus infection assists in the dissemination of virus within the neonatal CNS.

Authors:  Jenna M Tabor-Godwin; Chelsea M Ruller; Nolan Bagalso; Naili An; Robb R Pagarigan; Stephanie Harkins; Paul E Gilbert; William B Kiosses; Natalie A Gude; Christopher T Cornell; Kelly S Doran; Mark A Sussman; J Lindsay Whitton; Ralph Feuer
Journal:  J Neurosci       Date:  2010-06-23       Impact factor: 6.167

3.  Immunohistochemical analysis of the relationship between islet cell proliferation and the production of the enteroviral capsid protein, VP1, in the islets of patients with recent-onset type 1 diabetes.

Authors:  A Willcox; S J Richardson; A J Bone; A K Foulis; N G Morgan
Journal:  Diabetologia       Date:  2011-05-20       Impact factor: 10.122

4.  Persistence of Coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes.

Authors:  E K Alidjinou; I Engelmann; J Bossu; C Villenet; M Figeac; M-B Romond; F Sané; D Hober
Journal:  Virulence       Date:  2017-01-23       Impact factor: 5.882

5.  The role of autophagy during coxsackievirus infection of neural progenitor and stem cells.

Authors:  Jenna M Tabor-Godwin; Ginger Tsueng; M Richard Sayen; Roberta A Gottlieb; Ralph Feuer
Journal:  Autophagy       Date:  2012-06-01       Impact factor: 16.016

6.  MicroRNA-324-3p Plays A Protective Role Against Coxsackievirus B3-Induced Viral Myocarditis.

Authors:  Tingjun Liu; Jing Tong; Chen Shao; Junyan Qu; Hua Wang; Yi Shi; Yajing Lin; Yun Liu; Shihe Shao; Hongxing Shen
Journal:  Virol Sin       Date:  2021-10-11       Impact factor: 6.947

7.  Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors.

Authors:  Nadine Althof; J Lindsay Whitton
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

8.  Distinct neural stem cell tropism, early immune activation, and choroid plexus pathology following coxsackievirus infection in the neonatal central nervous system.

Authors:  Jenna M Puccini; Chelsea M Ruller; Scott M Robinson; Kristeene A Knopp; Michael J Buchmeier; Kelly S Doran; Ralph Feuer
Journal:  Lab Invest       Date:  2013-12-30       Impact factor: 5.662

Review 9.  Enterovirus infections of the central nervous system.

Authors:  Ross E Rhoades; Jenna M Tabor-Godwin; Ginger Tsueng; Ralph Feuer
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

10.  Antenatal and postnatal diagnosis of coxsackie b4 infection: case series.

Authors:  Jennifer C Hunt; Carol Schneider; Savas Menticoglou; Jayantha Herath; Marc R Del Bigio
Journal:  AJP Rep       Date:  2011-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.